Bio-Techne Corp TECH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TECH is a good fit for your portfolio.
News
-
BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS
-
BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY
-
BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE
-
BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS
-
BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES
-
BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA
-
BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM
-
BIO-TECHNE TO PRESENT AT THE BARCLAYS 26th ANNUAL GLOBAL HEALTHCARE CONFERENCE
Trading Information
- Previous Close Price
- $64.01
- Day Range
- $62.70–64.81
- 52-Week Range
- $51.79–89.91
- Bid/Ask
- $61.40 / $74.00
- Market Cap
- $9.86 Bil
- Volume/Avg
- 902,987 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- 33.18
- Price/Sales
- 8.85
- Dividend Yield (Trailing)
- 0.51%
- Dividend Yield (Forward)
- 0.51%
- Total Yield
- 1.32%
Company Profile
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 3,050
- Website
- https://www.bio-techne.com
Comparables
Valuation
Metric
|
TECH
|
TIHE
|
BIO
|
---|---|---|---|
Price/Earnings (Normalized) | 33.18 | — | 24.44 |
Price/Book Value | 5.02 | — | 0.96 |
Price/Sales | 8.85 | — | 3.20 |
Price/Cash Flow | 30.89 | — | 10.59 |
Price/Earnings
TECH
TIHE
BIO
Financial Strength
Metric
|
TECH
|
TIHE
|
BIO
|
---|---|---|---|
Quick Ratio | 2.54 | — | 4.01 |
Current Ratio | 4.37 | — | 5.83 |
Interest Coverage | 18.34 | — | −18.24 |
Quick Ratio
TECH
TIHE
BIO
Profitability
Metric
|
TECH
|
TIHE
|
BIO
|
---|---|---|---|
Return on Assets (Normalized) | 11.61% | — | 2.73% |
Return on Equity (Normalized) | 15.75% | — | 3.84% |
Return on Invested Capital (Normalized) | 13.09% | — | 2.95% |
Return on Assets
TECH
TIHE
BIO
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nktfyjlxj | Fcc | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mzpqhwzc | Tbghtt | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yyzppjjm | Tdvhfl | $98.9 Bil | |
MRNA
| Moderna Inc | Crgtjzhx | Nkvl | $39.7 Bil | |
ARGX
| argenx SE ADR | Vbnbfgzx | Fdxw | $22.1 Bil | |
BNTX
| BioNTech SE ADR | Mlkdmtxl | Hpvj | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gbywtqkny | Qcyrq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wptlmxmw | Crfjb | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qhbgkggsm | Jjxphkm | $12.3 Bil | |
INCY
| Incyte Corp | Mjkzkxqn | Wjmzzsw | $11.8 Bil |